PMID: 6981173Mar 1, 1982Paper

Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function

Reviews of Infectious Diseases
G R SiberA L Smith

Abstract

Thirty-seven children and adults aged 0.2-82 years were treated intravenously with 150 mg of trimethoprim (TMP) and 750 mg of sulfamethoxazole (SMZ)/m2 every 8 hr, usually for known or suspected pneumocystis pneumonia; when necessary dosage was adjusted to maintain peak TMP levels of 5-10 micrograms/ml. On day 2 of treatment, mean peak levels of TMP-SMZ were 7.02 and 148 micrograms/ml, respectively, and mean half-lives were 9.6 and 10.7 hr, respectively. All age groups achieved similar peak levels of TMP-SMZ, although dosages per weight were higher in children than in adults. Peak increments (peak levels minus levels before infusion) were higher and more reliable after iv than after oral dosage (P less than 0.001). The half-lives of TMP and SMZ increased with age (r = +0.73 and +0.39, respectively) and were correlated directly with the level of serum creatinine (r = +0.85 and +0.39, respectively). Serum concentrations of N4-acetyl-SMZ, the major hepatic metabolite of SMZ, increased in proportion to concentrations of creatinine in serum (r = +0.92; P less than 0.001). Adverse effects included fluid overload due to the large dilution volume and thrombocytopenia, which was associated with higher serum TMP levels and longer treatme...Continue Reading

Citations

Dec 1, 1994·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·E V Capparelli
Jan 1, 1985·Archives of Disease in Childhood·G W RylanceD G Roberts
Jun 10, 2014·Annals of Intensive Care·Glen R Brown
Apr 24, 1987·Pharmaceutisch Weekblad. Scientific Edition·T B VreeJ H Berden
Nov 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M BennettI Singer
Mar 7, 2019·Clinical Pharmacokinetics·Elizabeth J ThompsonMichael Cohen-Wolkowiez
Aug 12, 2017·British Journal of Clinical Pharmacology·Claire PressiatUNKNOWN MONOD Study Group
Jun 17, 2020·Journal of Clinical Pharmacology·Amer Al-KhoujaGilbert J Burckart
Sep 1, 1989·DICP : the Annals of Pharmacotherapy·C M Paap, M C Nahata
Nov 1, 2017·Antimicrobial Agents and Chemotherapy·Julie AutmizguineUNKNOWN the Pediatric Trials Network Steering Committee
Mar 14, 2019·Clinical Journal of the American Society of Nephrology : CJASN·Rachel F Eyler, Kristina Shvets
Aug 3, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Alessio StrazzullaSylvain Diamantis
Apr 28, 2021·Antimicrobial Agents and Chemotherapy·Yi Shuan S WuUNKNOWN Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee
Sep 24, 2021·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Brandon J TritleTristan T Timbrook

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.